NCT02335099View on ClinicalTrials.gov

Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions
End Stage Renal DiseaseVascular Access Patency
Interventions
DRUG

ticagrelor

ticagrelor 90 mg twice a day for 6 months

DRUG

Placebo

1 pill twice a day for 6 months

Trial Locations (1)

22908

University of Virginia - Hospital West Kidney Center Dialysis, Charlottesville

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University of Virginia

OTHER